Colleran David 4

4 · Anika Therapeutics, Inc. · Filed Mar 11, 2026

AI-generated summary of this filing

Updated Mar 12, 2026

Anika (ANIK) EVP David Colleran Receives RSUs; Shares Withheld

What Happened

David Colleran, EVP, General Counsel and Corporate Secretary of Anika Therapeutics (ANIK), had the third and final installment of an RSU award vest on March 9, 2026. The award converted 5,465 restricted stock units into common shares.
To satisfy tax withholding on the vested RSUs, 1,919 shares were retained by the company at $14.96 per share, totaling $28,708. The remaining shares were issued to Colleran.

Key Details

Transaction date: March 9, 2026; Form filed March 11, 2026 (timely).
Vesting: 5,465 RSUs converted to common stock (third and final installment of a 16,395 RSU grant made 3/9/2023).
Tax withholding: 1,919 shares withheld/disposed to cover tax liability at $14.96 per share for a total withholding value of $28,708 (footnote F3).
Other notes: Footnote F1 confirms each RSU converts to one share; footnote F2 notes Colleran also acquired 1,600 shares via the company ESPP in 2025 (800 on 5/14/2025 and 800 on 11/14/2025).
Shares owned after the transaction: Not specified in the provided filing excerpt.

Context

This was an RSU vesting event (award conversion), not an open-market purchase or a discretionary sale. The withholding of shares to cover taxes is a routine administrative action and does not necessarily indicate a buy/sell view on the stock.
The filing shows a cashless share withholding to satisfy tax obligations rather than a separate cash payment.

Form 4

Period: 2026-03-09

EVP, General Counsel, Corp Sec

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2026-03-09+5,465→ 55,019 total
Tax Payment
Common Stock
[F3]
2026-03-09$14.96/sh−1,919$28,708→ 53,100 total
Exercise/Conversion
Restricted Stock Unit
[F1][F4]
2026-03-09−5,465→ 0 total
→ Common Stock (5,465 underlying)

Footnotes (4)

[F1]Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
[F2]Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 800 shares purchased on May 14, 2025 and 800 shares purchased on November 14, 2025.
[F3]Reflects an aggregate of 1,919 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026.
[F4]On March 9, 2023, the Reporting Person was granted 16,395 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.

Signature

/s/ David Colleran|2026-03-11

1 file